Centralised Molecular Pathology for Rare Tumours: A National Feasibility Study of Real-Time Medulloblastoma Diagnostics by Crosier S et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Crosier S, Hicks D, Schwalbe E, Williamson D, Nicholson S, Michalski A, Pizer B, 
Bailey S, Bown N, Robson K, Wharton S, Jacques T, Clifford S.  
Centralised Molecular Pathology for Rare Tumours: A National Feasibility 
Study of Real-Time Medulloblastoma Diagnostics. 
In: 17th International Symposium on Pediatric Neuro-Oncology (ISPNO).  
12-15 June 2016, Liverpool, UK: Oxford University Press. 
 
Copyright: 
This is the authors’ manuscript of an abstract for a paper that was presented at the 17th International 
Symposium on Pediatric Neuro-Oncology (ISPNO) and published in Neuro-Oncology by Oxford University 
Press. 
DOI link to final published version: 
http://dx.doi.org/10.1093/neuonc/now076.75  
Date deposited:   
24/08/2016 
Embargo release date: 
01 June 2017  
S. Crosier1, D. Hicks1, E.C. Schwalbe, D. Williamson, S. Nicholson1, A. Michalski3, B. Pizer5, 
S. Bailey, N. Bown1, K. Robson2, S. Wharton4, T.S. Jacques3, S.C. Clifford1 
 
1Newcastle University, Newcastle, UK; 2Nottingham University Hospitals NHS Trust, 
Nottingham, UK; 3UCL Institute of Child Health and Great Ormond Street Hospital, 
London, UK; 4Sheffield University, Sheffield, UK; 5Alder Hey Children’s Hospital, Liverpool, 
UK 
 
E-mail: steve.clifford@ncl.ac.uk 
 
Centralised molecular pathology for rare tumours: A national feasibility study of real-
time medulloblastoma diagnostics 
 
Advanced diagnostic molecular pathology is becoming essential in contemporary clinical care; 
however, coordinated multi-centre approaches in rare diseases present specific challenges of 
centralisation, tissue/assay quality control, standardisation and rapid reporting. We undertook 
a national study in medulloblastoma (MB), to establish feasibility of rapid sample collection, 
consent, transportation, centralised pathology review (CPR) and assessment of established 
prognostic biomarkers, to underpin routine diagnostics and participation in international 
studies.  
 
Frozen and FFPE tissues were co-submitted to a National Reference Centre, which aimed to 
report results within 30 days post-surgery. 135 samples were received from 16 centres (2009-
present); complete CPR and biomarker analysis was achieved in 87% (118/135), with 
insufficient material the most common cause of failure. Late reporting was most often due to 
delayed submission. Twenty (15%) showed high-risk MYC/MYCN amplification; iFISH 
methods best reflected amplification status (vs. MLPA and 450K-derived copy number). β-
catenin IHC showed significant inter-observer variability; use of non-IHC methods (CTNNB1 
mutation, chromosome 6 status, 450K subgrouping) allowed more faithful definition of 
favourable-risk MBWNT status (14/135; 10%). CPR assigned variant (n=30) or modified the 
local diagnosis (n=10) in 40/135 (30%). Tumour material was assessed for use in 
contemporary genome-wide methods and was typically suitable for DNA methylation profiling 
(450K; 129/135, 94%), but commonly fell below QC requirements for RNA-seq (53/135, 39%). 
 
Delayed sample receipt, or submission of inadequate biopsies, represent significant risks to 
successful centralised diagnostics and investigative biological studies of rare tumours. 
Validation and stringent QC of specific biomarker assays is essential for robust treatment-
stratification in molecularly-driven clinical trials. 
 
